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ABSTRACT 
     In medical imaging, a wide variety of methods are used to interrogate structural and 
physiological differences between soft tissues. One of the most ubiquitous methods in 
clinical practice is Magnetic Resonance Imaging (MRI), which has the advantage of 
limited invasiveness, soft tissue discrimination, and adequate volumetric resolution. A 
myriad of advanced MRI methods exists to investigate the microstructural, physiologic 
and metabolic characteristics of tissue.  For example, Dynamic Contrast Enhanced (DCE) 
and Dynamic Susceptibility Contrast (DSC) MRI non-invasively interrogates the 
dynamic passage of an exogenously administered MRI contrast agent through tissue to 
quantify local tracer kinetic properties like blood flow, vascular permeability and tissue 
compartmental volume fractions. Recently, an improved understanding of the biophysical 
basis of DSC-MRI signals in brain tumors revealed a new approach to derive multiple 
quantitative biomarkers that identify intrinsic sub-voxel cellular and vascular 
microstructure that can be used differentiate tumor sub-types. One of these characteristic 
biomarkers called Transverse Relaxivity at Tracer Equilibrium (TRATE), utilizes a 
combination of DCE and DSC techniques to compute a steady-state metric which is 
particularly sensitive to cell size, density, and packing properties. This work seeks to 
investigate the sensitivity and potential utility of TRATE in a range of disease states 
including Glioblastomas, Amyotrophic Lateral Sclerosis (ALS), and Duchenne’s 
Muscular Dystrophy (DMD). The MRC measures of TRATE showed the most promise 
in mouse models of ALS where TRATE values decreased with disease progression, a 
finding that correlated with reductions in myofiber size and area, as quantified by 
immunohistochemistry. In the animal models of cancer and DMD, TRATE results were 
  ii 
more inconclusive, due to marked heterogeneity across animals and treatment state. 
Overall, TRATE seems to be a promising new biomarker but still needs further 
methodological refinement due to its sensitivity to contrast to noise and further 
characterization owing to its non-specificity with respect to multiple cellular features 
(e.g. size, density, heterogeneity) that complicate interpretation. 
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CHAPTER 1 
INTRODUCTION 
Magnetic Resonance Imaging Basics 
     Over the course of recent decades advances in medical imaging has created new 
opportunities to non-invasively interrogate the human body. One of the most prominent 
and ubiquitous methods is Magnetic Resonance Imaging (MRI), developed in the 1970s 
stemming from earlier research in physics investigating the polarization of nuclear spins, 
like protons, and their net magnetization when placed in a strong magnetic field as well 
as their response to radiofrequency (RF) radiation [1]. In general, MRI relies on the 
excitation of spins using radiofrequency pulses and detection of the subsequent RF 
radiation that occurs during spin relaxation.  The proton signal is measured via a RF coil, 
leveraging Faraday’s Law of Induction. Spatial localization can be achieved through the 
application of magnetic gradient fields that introduce spatially dependent frequency and 
phase of proton spins in a main magnetic field. After these perturbations, the recovery, 
also known as the relaxation, of the protons depends on the specific characteristics of the 
local proton environment and tissue composition. Since the body is comprised of 90% 
water molecules from soft tissues that are diverse in chemical structure and composition, 
it is possible to discriminate between soft tissues based on the proton populations in each 
tissue. For example, consider the difference in proton concentration between the 
cerebrospinal fluid (CSF) and grey matter.  In the CSF, a high proportion of hydrogen 
protons are present due to the fluid which provides a brighter signal compared to the grey 
matter containing a lower proportion of protons. In addition to soft tissue discrimination, 
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advance MRI techniques allow for the interrogation of factors such as water movement, 
chemical composition, and hemodynamic properties.  
      Before continuing to more advance techniques such as dynamic contrast imaging, it is 
useful to review the concepts of relaxation first. In the presence of a large magnetic field 
the magnetic moments of proton spins will align creating a net magnetization that is 
preferentially aligned in the direction of the applied field. After application of the RF 
pulse, the net magnetization is rotated away from this main field, which is conventionally 
defined as the Z-direction, and into the transverse (X-Y) plane. In MRI there are two 
main types of relaxation observed and measured as the net magnetization recovers to 
equilibrium.  First, T1 relaxation, or longitudinal relaxation time, characterizes the rate at 
which the net magnetization recovers to the original magnitude and alignment along the 
Z-axis prior to perturbation. As shown in Figure 1.1 the recovery of the Z-magnetization 
as a function of time after the application of the RF pulse (a) as well as the equation 
characterizing the relaxation (b).  
 
Figure 1.1 -Example of T1 Evolution with governing Equations 
 Biophysically, T1 relaxation occurs as the system of protons lose the energy imparted 
through the RF pulse and, accordingly, can be considered thermal relaxation. The energy 
is transferred to surrounding molecules in the external environment through collisions 
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and other electromagnetic interactions. The efficiency of this energy loss depends on the 
local biochemical composition of the tissue [2]. T1 weighted imaging is often used to 
determine structural and anatomic characteristics of tissue such as bulk atrophy in muscle 
and cerebellum, and cortical thickness of grey matter in the brain [2-4].  
 The second type of relaxation is T2 relaxation, which characterizes the rate of the 
decay of the magnetization in the transverse (X-Y) plane of signal. Biophysically, T2 
relaxation occurs through spin-spin interactions, diffusion and dephasing in the presence 
of local (microscopic) static field disturbances. In practice, the transverse magnetization 
decays much faster than dictated by T2 due to macroscopic field inhomogeneities or 
susceptibility induced field distortions. Thus, the observed T2 is defined as T2* and both 
times can be quantified through appropriate pulse sequence design. The general time 
course for T2 decay can be seen in Figure 1.2. 
 
Figure 1.2 - Example of T2 Decay with governing Equations 
 The T1, T2, and T2* relaxation times are the primary contrast mechanisms leveraged 
in the vast majority of clinical imaging. The times can be quantified through specialized 
pulse sequences that repeatedly sample the signal recovery (in the case of T1) or decay (in 
  4 
the case of T2 and T2*) over time. The resulting time profiles can be fit to well 
established logarithmic models of the decay(T2/T2*) or recovery (T1).  
    While these relaxation mechanisms are used to generate soft-tissue contrast in 
anatomic MR, the underlying biophysical basis of MR spin physics and contrast 
mechanism affords numerous opportunities to interrogate many additional relevant 
biological features. Key techniques used in clinical and research practice are MR 
Spectroscopy (MRS), Diffusion Imaging, functional MRI (fMRI), and Perfusion 
Imaging. In each of these sub-types there are a diverse set of techniques to glean more 
information from the proton signal. For example, consider diffusion imaging in which the 
voxel-wise Brownian motion of water movement can be measured by acquiring images 
with specially designed diffusion sensitive gradients [2].  Diffusion Imaging can also be 
leveraged to visualize white matter fiber tracks using the method known as Diffusion 
Tensor Imaging. Magnetic resonance spectroscopy can be used to interrogate the 
chemical composition within tissue by analyzing the chemical shift of molecules that 
have detectable spins (e.g. 1H, 31P, 13C). The MRS technique has been particularly 
useful in analyzing brain tumor environments and progression through monitoring of 
Choline (Cho) and N-acetyl aspartate (NAA) levels and ratios [5]. MRI is not only 
limited to assessing inherent features. With fMRI, composite changes in local blood 
oxygenation, blood flow and blood volume in response to different brain states or 
response to stimuli can be evaluated through dynamic measures of T2*-weighted MRI 
signals. With this technique it is possible to map specific regions of activation in relation 
to speech and language to aid in determining resection boundaries for surgery. 
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     It is the combination of all these techniques, that is used in current clinical practice 
and research. Unlike most other imaging modalities, MRI is able to provide a more 
comprehensive assessment of tissue anatomy, microstructure, physiology and 
biochemical composition, enabling physicians to make more confident diagnosis and 
plans of care. The extraordinary range of contrast mechanisms provided by MRI also 
serves as the basis for the development and application of novel biomarkers investigated 
in the studies described herein. 
Perfusion Imaging Basics 
     Dynamic imaging is often used to characterize the changes in a tissue’s MRI signal 
over time as paramagnetic contrast agent flows through the vasculature, into the 
extravascular space and back again. Intrinsic heterogeneity and pathology-induced 
changes in tissue microstructure give rise to differences in local contrast agent kinetics. 
Original work conducted in 1987 by Villrigner and colleges showed with T2 weighted 
imaging as Gd(DPTA)2- passed through the capillaries that the MRI signal intensity 
decreases [6]. This effect was determined to be caused by a difference between the 
magnetic susceptibility between the capillaries containing contrast and the surrounding 
tissue, inducing field gradients that decreased spin phase coherence and T2* [6]. This 
gave rise to the field that is now called Dynamic Susceptibility Contrast (DSC) MRI,  
which continues to leverage contrast agent induced signal decreases to interrogate local 
hemodynamics, primarily in the brain. Alternatively, it is possible to use Dynamic 
Contrast Enhanced (DCE) MRI which involves a T1 weighted imaging approach to detect 
concentrations of paramagnetic contrast agent and its dynamic passage through tissue. By 
utilizing the shortening effects of contrast agents on T1 relaxation it possible to detect 
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differences in the physiology and pathology of the tissue after the contrast agent is 
allowed to interact with the local environment causing an increase in signal intensity 
from the shortened T1 recovery [7].  
     An important consideration for both DSC-MRI and DCE-MRI are the quantitative 
tools that are needed to determine parameters such as concentration, Cerebral Blood Flow 
(CBF), Cerebral Blood Volume (CBV), Mean Transit Time (MTT), vascular 
permeability and/or the volume fraction of the extravascular, extracellular space (EES). 
For both methods these parameters can be extracted by applying pharmacokinetic models 
of tracer passage through the tissues of interest. Many of these models consider an array 
of hemodynamics features that can change the observed curve such as transfer of contrast 
agent between intravascular, extravascular, intracellular, and extracellular compartments 
[7-10]. Figure 1.2 shows an example two compartment model of contrast agent passage 
in the vasculature. Where kin and kout are the rate constants characterizing the influx and 
efflux of contrast agent into the system. The k1,2 and k2,1 transfer constants describe the 
passage of contrast agent between EES and blood-plasma.  
 
Figure 1.3– Generic Two Compartment Model of Tracer Kinetics 
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Another important caveat of perfusion imaging with MRI is that, as a modality, it does 
not directly detect the administered contrast agent. Rather, it detects the influence of the 
contrast agent on the intrinsic MR relaxation times. Consequently, in order to measure 
the voxel-wise contrast concentration it is necessary to characterize the relationship 
between the relaxivity of the tracer and the change in longitudinal and/or transverse 
relaxation rate ΔR1 and ΔR2, where R1 = 1 /T1 and R2 = 1/T2 [7]. As an example, 
Equation 1.1 shows the relationship between contrast agent concentration, R1 relaxation 
rate change, and the contrast agent relaxivity, where C(t) is the concentration in a given 
voxel at a point in time after contrast has been injected, R1(t) is the relaxation rate time 
profile, r1 is the longitudinal relaxivity of the contrast agent, and R10 is the baseline or 
pre-contrast longitudinal relaxation rate. Note that r1 is a constant that defines how 
effective a contrast agent is at inducing changes in T1. A similar constant and relationship 
can be described for contrast agent based T2 relaxation ranges.  𝑅"(𝑡) = 𝑟" ∙ 𝐶(𝑡) + 𝑅"+		        (Eq.1.1) 
     A feature that is unique to MRI is that it is not only limited to interrogating the 
passage of contrast agent for hemodynamic characterization, but it can also be used to 
glean inherent microstructural and morphological differences due to the biophysical basis 
of susceptibility-based contrast mechanisms. For example, by utilizing the contrast-agent 
changes in R2 and R2* it possible to obtain measures of mean vessel size in a voxel as 
shown by Tropès group [11]. Sensitivity to these structural characteristics originate from 
the susceptibility differences between tissue compartments (e.g. blood vessels and the 
EES), their volume fractions, their architecture and the induced magnetic field changes in 
response to contrast agent. As theorized by Yablonskiy and Haacke, the resulting signal 
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observed has a dependence on volume fraction, susceptibility of the medium and objects, 
local magnetic field, and the main magnetic field [12]. A subtlety to susceptibility 
contrast MRI methods involves the sensitivity of spin echo (SE) and gradient echo (GRE)  
pulse sequences to the radius of the underlying structures (e.g. vessels). Specifically, 
Kiselev et al. showed in Monte Carlo simulations that GRE sequences are sensitive to 
vessels of all sizes, whereas SE sequences are maximally sensitive to capillary sized 
vessels. [28]. The advantage of combining the two echo sequences provides a sensitivity 
to both large vessel and small vessel radii and enables interrogation of mean vessel size 
in a voxel. 
     The fields of DCE-MRI and DSC-MRI continue to push forward in utilizing 
innovations in hardware and pulse sequence design to allow for improved spatial and 
temporal resolution, extraction of new biomarkers, and standardizing acquisition and 
post-processing approaches to generate more reliable and reproducible results [13-14]. 
These efforts have increased the general use of these methods in both clinical practice 
and research, particularly in the fields of cancer and stroke imaging.  With the increased 
availability of higher field MRI, improved biophysical characterization of contrast 
mechanism and development of  and new types of contrast agents it is expected that this 
mature field will continue to experience the development of new methodologies and 
techniques. 
Magnetic Resonance Cytography 
     Historically, biophysical consideration of DSC-MRI contrast mechanisms focuses on 
the impact of contrast agents confined within vascular structures, because it is assumed 
that contrast agents do not extravasate. While this is typically true in normal brain, in 
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pathologies like cancer, the BBB is disrupted as part of the tumor angiogenic process. 
When this occurs the contrast agent is dynamically distributed between the vasculature 
and extravascular extracellular space. This contrast agent redistribution and its impact on 
perfusion measures required a new theoretical investigation in order to understand the 
factors that influenced the acquired DSC-MRI signals [15-16]. These efforts revealed that 
DSC-MRI data in tissues with a disrupted BBB are heavily influenced by both the 
vascular structure as well as the cellular microstructure (e.g. cell size, spacing, density, 
etc) [17]. This sensitivity to cellular features formed the underlying basis for what we 
now term Magnetic Resonance Cytography.  
Quarles et al developed a heuristical analytic model that characterizes the factors that 
contribute to ΔR2* data collected in brain tumors, including the extravascular 
extracellular (EES), extravascular intracellular (EIS), vascular space, the contrast agent 
concentration in each compartment, T2 contrast agent relaxivity, and the T2* contrast 
agent relaxivity that accounts for the microstructural properties of the vascular and 
extravascular compartment [15]. Soon after the administration of contrast agent, the 
concentration in the vascular space (Cp) and extravascular extracellular space (Ce) will be 
different. But after some time, the tissue of interest reaches a steady-state where Cp and 
Ce reach equilibrium [17]. At equilibrium (when Cp = Ce) there is no longer a 
susceptibility difference between the vascular and extravascular space and they are 
effectively as a single compartment, whose structure is defined by the three-dimensional 
distribution of cells. Note that clinical MRI contrast agents do not enter cells so there 
always remains a susceptibility difference between the vasculature and/or EES and the 
EIS. Another benefit of focusing on equilibrium is that we only need to consider the total 
  10 
tissue contrast agent concentration rather than trying to separately measure the 
concentration in the vessels and in the EES. At equilibrium, the R2* simplifies to 
Equation 1.2, and is a function of tissue contrast agent concentration, volume fractions, 
and compartmentalized relaxivities, where, r2 is the T2 relaxivity of the contrast agent, vi 
is the EIS volume fraction, ve is the EES volume fraction, vp is the vascular volume 
fraction, r*2p and r*2e are the T2* relaxivities of contrast agent in the vascular space and 
EES respectively, and Ct is the concentration in the voxel [17]. Δ𝑅2∗ = 0𝑟1 + 2324526 7𝑣9𝑟19∗ + 𝑣:𝑟1:∗ ;< 𝐶=        (Eq. 1.2) 
The bracketed term in Equation 1.2 consists only of static terms and serves as an effective 
transverse relaxivity that we term the transverse relaxivity at tracer equilibrium (r*2t,eq) or 
TRATE [17]. With this notation TRATE can be computed as:  𝑇𝑅𝐴𝑇𝐸 = 𝑟1=,:B∗ = CDE∗FG     (Eq. 1.3) 
Experimentally, a specialized MRI protocol needs to be employed (beyond 
straightforward single-echo DSC-MRI) for MRC measures of TRATE, which requires 
the simultaneous quantification of ΔR2* (that is free of T1 effects) and ΔR1 so that Ct can 
be directly measured, using the conventional notation found in DCE-MRI (Ct= ΔR1/r1). 
To simultaneously measure ΔR2* and ΔR1 we can utilize a dynamic multi-echo 
acquisition strategy and also collect a pre-contrast T1 map.       
Using computational simulations, Semmineh et al. showed that TRATE is highly 
sensitive to variations in cell size and density. With in-vivo data and ex-vivo histologic 
validation, TRATE was found to significantly differ between brain tumor animal models 
that exhibit dissimilar cellular features. These initial efforts provided the basis for the use 
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of TRATE as a biomarker of cytographic features in a range of pathologies and organs, as 
evaluated herein. 
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CHAPTER 2 
AMYOTROPHIC LATERAL SCLEROSIS MODEL 
Disease Introduction 
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a 
neurodegenerative disease characterized by the progressive loss of upper and lower motor 
neuron function. This loss of function leads to symptoms such as muscular weakness and 
abnormalities early on, then developing into fatal difficulty of breathing and swallowing 
[16,17]. ALS prevalence is 5 cases per 100,000 in the U.S, this may be due to longer life 
expectancies and increased awareness of the disease from advances in medicine [16,18]. 
From onset, the life expectancy of patients tends to be 30 months to 5-10 years and varies 
depending on the type, and anatomic location of onset atrophy [19]. Even so, there are 
many therapies in development and ongoing research that is aimed at stopping 
degeneration of motor neurons or halting the process to extend lifespans [18]. 
     Biomarkers for ALS have been difficult to find and implement [16]. Current 
diagnostic techniques involve electro-conductivity studies, cerebrospinal fluid analysis, 
and neuroimaging [16,20]. Imaging techniques range from analysis of the structure of 
cortico-spinal tracts, cortical thickness and volumetric measurement of the afflicted 
muscle [16,20-23,26]. These techniques include analyzing the differences between 
healthy and diseased tissue utilizing T2 and T2* weighted magnetic resonance imaging 
(MRI) for identifying fat infiltration and ADC [24,25]. In similar disease states where 
muscle dystrophy occurs, MRI has been used to study structural changes associated with 
muscle degeneration [26,27]. 
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      When considering the physiological effects of this disease it is important to 
understand what atrophy does to muscles. Muscle atrophy is considered an active process 
controlled by signaling pathways, in which degradation of muscle growth factors that are 
used in protein synthesis are targeted [29]. Complex signaling pathways and factors are 
involved in normal muscle growth, but in muscular atrophy there are many signaling 
factors that are either inhibited or missing leading to a decrease muscle mass, myo-fiber 
size, and their distribution [29]. In ALS, the loss of α-motor neuron signaling leading to 
atrophy occurs at later stages of the disease where symptoms are already onset, detecting 
the progression of this atrophy is important for prognosis and quality of care. This 
detection of atrophy, is a prime opportunity for TRATE to be utilized for the assessment 
of myofiber changes. 
Methods 
Animal Model 
     In this study 8 SOD1 mice with strain B6.Cg-Tg(SOD1*G93A)1Gur/J and 8 Control 
mice where obtained from Jackson Laboratories. The mice were then imaged at 9 weeks, 
12 weeks, and 15 weeks old to observe onset to late stage progression.  All experiments 
and care for the mice were carried out in accordance with our institution’s animal care 
and use polices. At each time point a control mouse and an ALS mouse were sacrificed 
for histology. Histological analysis was used to quantify the distribution of myofiber 
diameters, and myofiber area and number.  
Image Acquisition 
      The mice were imaged with a 7 Tesla Bruker Scanner utilizing a 72mm transmit and 
read volume coil. Similar to the protocol applied in Semmineh et al. a pre-contrast T1 
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images was acquired using a Variable Recovery Time (VTR) sequence with parameters: 
Repetition Time (TR) = [350ms, 500ms, 1000ms, 1500ms, 3000ms, 5000ms], Echo Time 
(TE) = 11ms, Field of View (FOV) = 30 mm2, Slice Thickness = 1.5mm, Flip Angle (FA) 
= 90°, Matrix = 150x150x6. Once the T1 was acquired, we collected dynamic MRC data 
using  a multi-Echo gradient and spin echo sampling of the FID (GESFIDE) with the 
following parameters: TR = 350ms, 8 Echoes with spacing 1.96ms with start TE1 = 2.4ms 
and end TE8 = 23.7ms, FOV = 30mm2, Slice Thickness = 1.5mm, FA = 90°, Dynamics = 
40, Matrix = 98x98x6x40. A 0.2mM/kg dose of Gadavist (0.1mM/mL concentration) was 
administered after the 5th dynamic.  To administer the contrast agent, a tail vein 
catheterization was performed to allow for an injection administered from a Genie Touch 
Syringe Pump (Lucca Technologies) at a rate of 1ml/min. MRC data was acquired for a 
total of 22 minutes after contrast agent injection. A GRE and SE sequence was utilized in 
order to determine, for the first time, if spin echo based TRATE values could be detected 
in muscle tissues. We focused our analysis in this study on the GRE data. 
Data Analysis 
      In order to obtain relevant T2, T2*, and T1 values, scans underwent a voxel-wise non-
linear fitting utilizing a Levenberg-Marquardt algorithm with MATLAB’s built-in 
lsqcurvefit function to determine relaxation values. In the case of the T1 VTR scan, the 
resulting pre-contrast T1 map was used to obtain dynamic T1 values from the GESFIDE 
sequence. By utilizing the spoiled gradient recalled equation to find instantaneous R1 a 
dynamic curve can be obtained from the first echo of the DSC signal, which has minimal 
T2* contribution [10]. Calculation of pre-contrast T1 signal S0 from the GESFIDE 
sequence is shown in equation 2.1 where α is Flip Angle, TR is repetition time of the 
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GESFIDE sequence, S_ is average baseline signal from the GESFIDE of the first echo 
TE1, and T1 is the pre-contrast T1 map. 
𝑆+ = 𝑆I JK"I:LMNMOPQR	STUJK"I:LMNMOT∗(RVWS	)U      (Eq. 2.1) 
From this calculation we can obtain an instantaneous R1 value at each dynamic to 
calculate a ΔR1 value in given voxel with the TE1 signal of the GESFIDE sequence at 
each time timepoint t. 𝑅1(𝑡) = I"YD ln \](=) ^_` SI]a `bc S](=)I]a`bcS 	d        (Eq. 2.2) 
With ΔR1 values we can use Equation 1.1 and the r1 relaxivity for Gadavist to calculate 
the concentration (Ct) in the voxel at each dynamic. By utilizing the last 5 dynamics of 
the GESFIDE data (approximately four minutes) as our equilibrium time frame we are 
able to calculate voxel-wise TRATE with Equation 1.3. To ensure data quality, 
thresholds are applied for specific signal to noise ratios (SNR) and contrast to noise ratio 
(CNR) minimums. Regions of Interests (ROI) were drawn to encompass the whole 
gastrocnemius, lateral gastrocnemius, and medial gastrocnemius making sure to avoid 
bone.  
Results 
     Figure 2.1 shows the extracted concentration and ΔR2* dynamic time profiles in 15-
week-old SOD1 and control mice. These curves are averaged across voxels in the whole 
gastrocnemius muscle. Note that the magnitude of the curves are not necessarily due to 
physiological differences but because of an unexpected experimental confound that led to 
dose variability. This dose variability does not confound the estimation of TRATE 
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(assuming sufficient CNR) because its calculation accounts for the delivered dose. It is 
important to note from these curves that we see robust concentration and ΔR2* values at 
time points well past the initial tracer delivery (e.g. >15 minutes) where equilibrium can 
reasonably be expected. It is also important to distinguish that equilibrium does not 
necessarily imply a constant Ct but rather that Cp = Ce.   
 
Figure 2.1 – Comparison of characteristic concentration and ΔR2* curves in the 
gastrocnemius muscle 
  
 
Figure 2.2 – Comparison of TRATE maps of the Gastrocnemius 
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In Figure 2.2 we see the spatial distribution of TRATE values in the gastrocnemius 
between a characteristic control and ALS mouse at 12-weeks-old where the range is from 
0-1000 (mmol-s)-1. Colored voxels are the voxels with reasonable SNR and CNR to be 
used in comparisons. Two main observations are that in both control and ALS mice the 
distribution of TRATE values is very heterogenous, and that there appears to be a larger 
amount of high TRATE values in the control mice when compared to the ALS mice.  
 
Figure 2.3 – Histogram distribution of TRATE values at 15-Weeks 
Figure 2.3 illustrates the histogram of TRATE values in 15-week-old control and ALS 
mice across all voxels. Note the shift in the ALS mice towards lower TRATE values as 
compared to controls which are centered around 300 (mmol-s)-1. 
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Figure 2.4 – Boxplot of Average TRATE Values Over Time 
Figure 2.4 shows the range of TRATE values in 9-week, 12-week, and 15-week old 
control mice, most commonly varied between 300 to 400 (mmol-s)-1.  As expected, 
TRATE values remained constant over the course of the study (p = 0.483). It is critically 
important to note that the magnitude of these TRATE values far exceed to reported T2 
relaxivity of Gadovist (~ 4 (mmol-s)-1), indicating that the measured T2* effects are 
originating from the much stronger susceptibility effects that give rise to TRATE.  The 
TRATE values in the ALS group at 9 weeks were comparable to controls (which is 
consistent with known histopathology) but are observed to decrease significantly over 
time (p = 0.003), with values ranging from 100 – 200 (mmol-s)-1 at 15 weeks.  Sample 
sizes were 9-weeks (Control n = 8, ALS n = 8), 12-weeks (Control n = 5, ALS = 6), and 
15-weeks (Control n = 4, ALS = 5).  
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Figure 2.5- Immunofluorescence Imaging of Muscle Sample using DAPI (Blue), 
Laminin(Green), and Heavy Chain Myosin Stain (Red). 
Figure 2.5 shows Immunofluorescence DAPI, and CD98 antibodies staining for nuclei 
and plasma membrane of myofibers in the gastrocnemius at 15-weeks of disease 
progression. As compared to control mice, the myofibers in ALS mice were smaller in 
diameter and much less uniform.  Figure 2.6 shows the quantitative analysis of individual 
myofiber data and further confirms the reduction in cell area and minimum fiber 
diameter. 
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Figure 2.6 – Histologic Analysis of Cell Area and Minimum fiber diameter. 
Discussion  
     These results indicate that TRATE is sufficiently sensitive to tissue cytographic 
features such that it is able to detect progressive myofiber degeneration in mouse models 
of ALS.  Histological analysis confirmed the expected reductions in myofiber area and 
size, and provide a mechanistic underpinning for the measured TRATE changes. These 
results are also consistent with previous simulations in our lab demonstrating that 
TRATE decreases with cell size. 
As this was the first application of MRC outside the brain a number of experimental 
challenges were observed and had to be overcome. First, as noted above, tail vein bolus 
injections yielded highly variable doses across mice, which was confirmed by 
investigating contrast agent concentration in voxels within arterial vessels. In cases where 
the dose was lower than desired, the CNR within muscle was, at times, prohibitive for 
MRC analysis, requiring the development of systematic voxel-wise quality control 
measures. These measures ensured that only voxels exhibiting robust T1 and T2* changes 
were considered for analysis. In the next round of experiments, we are addressing this 
issue using a continuous infusion approach with a predetermined contrast agent 
concentration threshold within the muscle as a stopping point for the infusion. 
Another challenge presented in the ALS mouse was reliable methods for ROI 
delineation due to the progressive degeneration and wasting of the muscle, resulting in 
substantially reduced muscle volumes. Finally, we expect that a potential source of the 
marked (and unexpected) heterogeneity in TRATE values in both control and ALS mice 
is the spatially dependent orientation of individual myofibers with respect to the main 
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magnetic field. Biophysically, it is well known that magnetic fields surrounding 
perturbers, like a long cylinder, are dependent on the angle of the perturber with respect 
to the applied field. The orientation dependency could be exacerbated if the legs of each 
animal were not reproducibility positioned during each scan.  Future studies will seek to 
explore the biophysical basis of this as it would inform future clinical implementation.    
Conclusion  
The results of this longitudinal experiment support the use of TRATE as a 
biomarker for muscle atrophy in a preclinical model of ALS. Further work is needed to 
identify when TRATE is able to identify the earlier stages of muscle degeneration.  
Histological analysis indicates that TRATE changes originate, in part, from reduced 
myofiber size. Further validation of TRATE’s sensitivity to muscle degeneration would 
enable the use of MRC as a biomarker for preclinical pharmaceutical and biologic 
therapy targeting atrophy. Moving forward, it will be important to combine this technique 
with whole body imaging to consider the sporadic and random nature of initial onset 
locations of atrophy, while also observing the atrophy progression of critical areas such 
as the glossopharyngeal muscles, diaphragm and heart.  
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CHAPTER 3 
GLIOBLASTOMA MODEL 
Disease Introduction 
     Observing the progress of cancer research over the past few decades is remarkable 
when considering the short time span and the amount of knowledge learned. 
Understanding of tumor genetics, microenvironment, progression, and causal factors has 
spurred a new respect for the complexity of the disease. A major variant of cancer that is 
in the spotlight and a focus of research is the Glioblastoma which can range in severity 
from Grade I – IV. Glioblastoma is one the most lethal forms of brain cancers which can 
have a survival rate of 1-2 years for Grade III-IV. There are many variations and sub-
types of glioblastoma tumors, treatments that may work for some may not work for 
others. Classifications for many of the sub-types of Glioblastoma is based on their 
genetic, histologic, and apparent structural or functional characteristics [31]. 
Understanding of the genetics and tumor microenvironment (TME) presented by Quail 
and Joyce point out many of the players in the TME that allow for growth and survival, 
particularly the compromised cells like astrocytes, macrophages, microglia, and 
lymphocytes that are essentially hijacked to promote tumor survival and evolution by 
regulating expression pathways and evading the natural immune response [32]. Tumor 
survival is dependent of the amount of nutrients it can receive to grow, and this is 
achieved, in part, via upregulated angiogenesis [32].  
     There are many MRI techniques possible for the characterization of brain tumors from 
MRS to static contrast enhanced T1 weighted images. Currently perfusion imaging is 
used to make parametric maps to aid in resection of the tumor, and to reliably identify 
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tumor progression and treatment response [13]. As noted in Chapter 1, the disruption of 
the BBB due to tumor associated angiogenesis is often a challenge for robust DSC-MRI 
measures of CBV.  The disrupted BBB and immature vasculature allow for contrast agent 
to extravasate, introducing additional simultaneous T1 and T2* changes that can be 
leveraged for estimating MRC parameters like TRATE.  In the original model in which 
TRATE was developed for Semmineh et al. showed the capability of TRATE to 
differentiate between C6 and 9L tumors in rats [15].  
     A key use of MRI in brain tumor patient care is the detection and monitoring of 
glioblastomas’ response to treatment. Whether it’s determining the response to 
chemotherapy or post-resection, it is important to detect a tumor recurrence early for 
better patient outcomes. One chemotherapeutic used commonly is temozolomide (TMZ) 
which utilizes the methylation of DNA to destroy tumor cells [33]. Effective TMZ 
treatment has been known to lower CBV values in the U251 brain tumor animal model 
implanted in rats [34]. In addition, TMZ has been shown to arrest growth of tumor cells, 
reduced proliferation, and induced apoptosis [35]. Although these examples are in rat 
models, similar results have been shown in mice [36]. 
Methods 
Animal Model 
     In this study 12 immunodeficient mice (Taconic Laboratories) had tumors induced via 
intracranial injection with human glioblastoma cell line ATCC-U87 tumor cells at 6-
weeks-old and were allowed to proliferate for two-weeks before treatment with TMZ 
began. The treatment regime consisted of a dose protocol of 50mg/kg five days a week. 
The control cohort included vehicle treatment with Orablend. All mice were imaged at 8-
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weeks-old to assess tumor progression and at 11-weeks-old to determine tumor response 
to therapy. All experiments and care for the mice were carried out in accordance with our 
institution’s animal care and use polices. 
Image Acquisition 
     The mice were imaged with a 7 Tesla (T) Bruker Scanner utilizing a 72mm transmit 
and read surface coil. Similar to the protocol applied in Semmineh et al. a pre-contrast T1 
images was acquired using a Variable Recovery Time (VTR) sequence with parameters: 
Repetition Times TR = [250ms, 500ms, 1000ms, 1500ms, 3000ms, 5000ms] TE = 11ms, 
FOV = 20 mm2, Slice Thickness = 0.5mm, FA = 90°, Matrix = 200x200x4. Once the T1 
map was acquired, a DSC sequence was acquired using a multi-Echo GESFIDE sequence 
was acquired with the following parameters: TR = 350ms, 8 Echoes with spacing 4.86ms 
with start TE1 = 3.8ms and end TE8 = 46.6ms, FOV = 20mm2, Slice Thickness = 0.5mm; 
FA = 90°, Dynamics = 45, Matrix = 100x100x4x45. A 0.2mM/kg dose of the contrast 
agent, Gadavist, was injected during the scan. To administer the contrast, a tail vein 
catheterization was performed to allow for an injection administered from a Genie Touch 
Syringe Pump (Lucca Technologies) at a rate of 1ml/min. The contrast was administered 
after an adequate baseline around 5-10 dynamics or 8-9min into the scan, and scanning 
was complete after 45 dynamics or 26 minutes. 
Data Analysis 
     A similar analysis to that used in Chapter 2 was implemented, except ROIs were 
drawn to encompass signal enhancing regions of the brain. Care was taken to avoid 
necrotic regions, in some cases necrosis of the region was too advanced causing the data 
point to be removed. 
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Results 
 
 
Figure 3.1 – Representative concentration and ΔR2* time profiles in enhancing tumor 
region. 
Figure 3.1 shows examples of the dynamic concentration and ΔR2* curves obtained.  
Concentration profiles are reasonable and match prior studies but, interestingly, the 
magnitude of the T2* effects in brain tumors decay much more rapidly than observed in 
muscle (Figure 2.1). Similar to the challenges noted in the ALS study, the administered 
doses were variable and those represented in the figure were selected from each group 
based on the distance from the mean of the distribution.  
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Figure 3.2 –TRATE maps in Non-TMZ treated and TMZ treated sample mice 
From Figure 3.2 we can see the TRATE spatial distribution for one mouse in each group.  
 
Figure 3.3 – Bar Graphs of Tumor Size and Averaged ROI TRATE Values 
Figure 3.3 shows the bar graphs of tumor size and averaged TRATE values in the signal 
enhancing region where Scan 1 had six Control and five TMZ treated, and Scan2 had five 
Controls and TMZ treated mice. From the tumor size graph, we are seeing comparable 
results to that of Rao et. al. where the untreated mouse tumors are growing significantly 
and the TMZ treated mouse tumor growth was halted. Pre-treatment TRATE values 
between the two cohorts of animals were consistent. Surprisingly, TRATE values 
exhibited a non-significant decrease in both cohorts of animals after treatment with both 
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vehicle and TMZ.  Despite this change in average scores for TRATE between the two, a 
two-sample t-test with 0.05 significance values yielded a failure to reject to the null 
hypothesis of the means being equal.
 
Figure 3.4 – Hematoxylin and Eosin Stain of Tumor Samples 
Figure 3.4 provides the histology for the treated and untreated tumors. In the control case 
we can see smaller tumor cells and a sparse distribution, while in the TMZ case we see 
larger tumor cells and a more clustered cell grouping. It is still not clear, whether there is 
a significant structural difference between the two. 
Discussion 
     Considering the results, it is difficult to determine whether TRATE is detecting the 
cellular changes in response to Temozolomide. It is clear that a more detailed analysis of 
the histologic features and their differences before and after vehicle and TMZ treatment 
is necessary in order to fully interpret the TRATE results. Unfortunately, we do not have 
pre-treatment histology images for comparison in each cohort which makes it impossible 
to know if the underlying pathology changed between time points.   It is feasible that the 
use of region of interest analysis in this study confounds the use of TRATE as a marker 
of treatment response because information about regional and individual heterogeneity is 
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lost. For example, animal models of brain cancer have increasing amounts of focus 
necrosis during tumor growth and that would tend to reduce TRATE values and could 
mimic treatment-induced cell death. Voxel-wise changes in biomarker data, a method 
called parametric response mapping, has shown increased predictive ability in brain 
cancer patients undergoing therapy, as compared to traditional ROI analysis. Future 
studies will seek to implement this method for the TRATE data collected herein. 
Conclusion  
     TRATE has shown the capability of differentiating between brain tumor cell types in 
prior studies but did not show efficacy for detecting treatment induces changes. If 
TRATE ultimately provides sensitivity to treatment response in future studies, it can 
easily be acquired as part of a multi-echo perfusion scan that are acquired routinely.  
Ultimately, while preclinical studies of this nature are useful for characterizing the 
biophysical basis of contrast mechanisms like MRC, clinical studies are required to 
assess their true potential to alter therapeutic decisions. Interestingly, such clinical studies 
are surprisingly easier than the animal studies conducted herein due to easier contrast 
agent injections, higher contrast to noise and much larger tumor volumes. 
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CHAPTER 4 
CONCLUSION 
     The development of minimally invasive biomarkers is an important field of research 
for prognosis and detection. Non-invasive means such as MRI allow for a higher 
frequency of sampling patient’s disease progression. TRATE should be seen a biomarker 
that adds sub-voxel cellular structural information to already established quantitative 
assays of diseased tissues. In the case of muscle dystrophies, TRATE can be utilized as a 
prognosis tool to assess the degree of atrophy or wasting on the cellular level. In the field 
of the cancer, TRATE can be seen as an additional classification tool to established 
quantitative markers that interrogate tumors. While TRATE cannot replace histology, it is 
possible to glean a sense of underlying cellular structure and use this information to 
determine care prior to biopsy of tumor or serum analysis. TRATE has a series of 
milestones to achieve prior to being widely accepted, such as clinical validation, 
advanced histologic conformation, and applications in other disease states. To TRATE’s 
benefit it does not require major changes in imaging protocols in the case of gliomas to 
be adopted since quantitative perfusion imaging is already implemented in many 
treatment routines. Moving forward, it will be important to create more efficacy and 
validation experiments to further understand the nuances of this technique. Currently, 
TRATE is being applied to human ALS studies and is showing promising and parallel 
results to the study conducted in this work. Overall, TRATE is in a nascent stage of 
development but shows tremendous promise and potential impact.  
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function [] = fidreader; 
%%%%%%%%%%%%%%%%Generates Signals and Parameters files for all relevent 
scans 
%%%%%%%%%%%%%%AF Q1 2018 Adaptation from BrukerImageProcessor AM Stokes 
%%%%%%%%%%%%Make sure fid is 16 bit otherwise manually read the file as 
%%%%%%%%%%%%32bit with fread function 
%Get the current directory (Mouse/Patient File) 
dirname = pwd; 
%%% Search through directory for scans 
    for a = 1:40 
        try 
            BRUKER_FILE1=[dirname '/' num2str(a) 
'/pdata/1/2dseq'];   %This program uses the processed 2dseq file. 
            pars = readnmrpar([BRUKER_FILE1(1:end-13) 'method']); 
            display(['The method for scan number ' num2str(a) ' is ' 
pars.Method '.']);        
        catch 
        end 
    end 
%%%%%Choose the scans you want processed 
scans = input('Enter the Scan number you would like processed in a 
vector ex : [ 1 ...n]'); 
%%%Processing For loop 
for k = 1: length(scans) 
    clear BRUKER_FILE1 pars Nechoes 
    BRUKER_FILE1=[dirname '/' num2str(scans(k)) '/pdata/1/2dseq']; 
    pars = readnmrpar([BRUKER_FILE1(1:end-13) 'method']); 
    visu = readnmrpar([BRUKER_FILE1(1:end-5) 'visu_pars']); 
    NpointRD=pars.PVM_Matrix(2);       %Size of read direction matrix 
    NpointPE=pars.PVM_Matrix(3);      %Number of phase encode steps 
    ns = pars.PVM_SPackArrNSlices(2); %Slices 
    if length(pars.PVM_Matrix) > 3 %%for 3D acq 
        ns=pars.PVM_Matrix(4); 
    end 
%%% Account for the Possible Inputs 
switch pars.Method 
    case 'gESFIDE' 
        Nechoes = pars.NEchoes; 
        dyn = pars.PVM_NRepetitions; 
    case 'MGE' 
        Nechoes = pars.PVM_NEchoImages; 
        dyn = pars.PVM_NRepetitions; 
    case 'MSME' 
        Nechoes = pars.NEchoes; 
        dyn = pars.PVM_NRepetitions; 
    case 'RAREVTR' 
        Nechoes = pars.MultiRepetitionTime(1); 
        dyn = pars.PVM_NRepetitions; 
        pars.RECO_wordtype(2:3) = '16'; 
    case 'RARE' 
        dyn = pars.PVM_NRepetitions;      
    case 'EPI' 
        dyn = 0; 
        Nechoes = pars.PVM_NRepetitions; 
    case 'DtiStandard' 
        dyn = 0; 
        ns = pars.PVM_SPackArrNSlices(2); %Slices 
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        Nechoes = pars.PVM_DwNDiffExp; 
        NpointRD=visu.VisuCoreSize(2);       %Size of read direction 
matrix 
        NpointPE=visu.VisuCoreSize(3); 
    case 'DtiEpi' 
        dyn = 0; 
        ns = pars.PVM_SPackArrNSlices(2); %Slices 
        Nechoes = length(pars.PVM_DwEffBval)-1; 
        NpointRD = pars.PVM_Matrix(3); 
        NpointPE = pars.PVM_Matrix(2); 
         
  
         
end 
%%%%Assigning bit integer 
try  
    pars.RECO_wordtype; 
catch 
    pars.RECO_wordtype(2:3) = '16'; 
end 
%%%%%%Read Fid 
fid1=fopen(BRUKER_FILE1,'r','l');   %Open fid 
fidmix1=fread(fid1,inf,['int' pars.RECO_wordtype(2:3)]);    %Read fid 
data as single line 
if dyn>2 
        
signal=reshape(fidmix1,NpointRD,NpointPE,Nechoes,ns,dyn);    %Reshape 
data into read and phase encode directions 
        else 
        signal=reshape(fidmix1,NpointRD,NpointPE,ns,Nechoes);%Reshape 
data into read and phase encode directions 
end 
signal = imrotate(signal,270);  %Rotate image 270 degrees 
signal = fliplr(signal);        %Flip image left to right 
cd([dirname '/' num2str(scans(k))]) 
twodseqcorr(signal,pars) 
cd([dirname]) 
  save([dirname '/' num2str(scans(k)) '/signal.mat'],'signal','pars') 
end 
    clear k 
end  
function [T2data] = T2mapp(signal,pars) 
%% 2dseq Correct 
function [] = twodseqcorr(signal,pars) 
Size = size(signal); 
Visu = readnmrpar('pdata/1/visu_pars'); 
VisuSlopeConsant = Visu.VisuCoreDataSlope(2:end); 
VisuOffeset = Visu.VisuCoreDataOffs(2:end); 
if length(Size)>4 
    [nx, ny, ne, nz, dyn] = size(signal); 
    VisuSlopeConsant = reshape(VisuSlopeConsant,[ne nz dyn]); 
    VisuOffeset = reshape(VisuOffeset,[ne nz dyn]); 
    VisuSlopeMatrix = ones(nx,ny,ne,nz,dyn); 
    VisuOffesetMatrix = ones(nx,ny,ne,nz,dyn); 
    for j  = 1:dyn 
        for k = 1:nz 
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            for l = 1:ne 
               VisuSlopeMatrix(:,:,l,k,j) = 
squeeze(VisuSlopeMatrix(:,:,l,k,j)) *VisuSlopeConsant(l,k,j); 
            end 
        end 
    end 
     for j  = 1:dyn 
        for k = 1:nz 
            for l = 1:ne 
               VisuOffesetMatrix(:,:,l,k,j) = 
squeeze(VisuOffesetMatrix(:,:,l,k,j)) *VisuOffeset(l,k,j); 
            end 
        end 
    end 
else 
    [nx, ny, nz, ne] = size(signal); 
    VisuSlopeConsant = reshape(VisuSlopeConsant,[nz ne]); 
    VisuOffeset = reshape(VisuOffeset,[nz ne]); 
    VisuSlopeMatrix = ones(nx,ny,nz,ne); 
    VisuOffesetMatrix = ones(nx,ny,nz,ne); 
    for l = 1:ne 
        for k = 1:nz 
        VisuSlopeMatrix(:,:,k,l) = squeeze(VisuSlopeMatrix(:,:,k,l)) 
*VisuSlopeConsant(k,l); 
        end 
    end 
    for l = 1:ne 
        for k = 1:nz 
        VisuOffesetMatrix(:,:,k,l) = 
squeeze(VisuOffesetMatrix(:,:,k,l)) *VisuOffeset(k,l); 
        end 
    end 
end 
Final2dseq = signal.*VisuSlopeMatrix+VisuOffesetMatrix; 
signal = Final2dseq; 
save('signalcorr.mat','pars','signal') 
function []  = T1mapp(signal,pars) 
  
%% T1 Processing 
%%%%%%%%%%%%%%%%%%%AF Q1 2018 Adaptation of BrukerImageProccessor A.M 
Stokes %%%%%%%%%%%%%%%%% 
%Takes in VTR volume and fits a T1 curve using lsqcurvefit 
%You need an ROI, Signal Volume, and parameter file 
%Get ROI using ROIgen %Get Signal Volume and Pars from FID2Sig  
%% Pre allocating 
TR = pars.MultiRepetitionTime(2:end); 
NTR = pars.NumT1Exps; 
[nx, ny, ns, ne] = size(signal); 
T1_map = zeros(nx,ny,ns); 
S0_map = zeros(nx,ny,ns); 
error_map = zeros(nx,ny,ns); 
LB = []; 
UB = []; 
options = optimset('TolFun',1e-9,'Tolx',1e-
9,'MaxIter',1000,'Display','off','Algorithm','levenberg-marquardt'); 
%% For Loop 
        parfor z = 1:ns 
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            disp(z) 
            for x = 1:nx 
                for y = 1:ny 
                        data= squeeze(signal(x,y,ns,:));                
                        voxel_data = data; 
                        params = [2000 max(voxel_data)]; %initial 
guesses [T1 So]               
                        [output, resid] = 
lsqcurvefit('t1_vtr_cf',params,TR',voxel_data,LB,UB,options); 
                        T1_map(x,y,z) = output(1); 
                        S0_map(x,y,z) = output(2); 
                        error_map(x,y,z) = resid;                      
                end 
            end 
        end 
        figure;imagesc(T1_map(:,:,3),[0 4000]);title(['T_1 map for 
slice ' num2str(2)]);colorbar; axis square off; 
        disp('Finished processing T1 maps, saving now') 
        dirname = pwd; 
        save([dirname '/T1map.mat'],'T1_map','S0_map','error_map'); 
    end 
  
  
 
 
%% T2 Processing 
%%%%%%%%%%%%%%AF Q1 2018 Adaptation of Bruker Image Processor A.M 
Stokes 
%Takes in GESFIDE Volume and fits for T2 and T2* using lsqcurve and 
%Piecewise Equation Ma. Wheril  
%% Pre Allocating 
[nx, ny, ne, ns, NTR] = size(signal); 
S1m = nan(nx,ny,ns,NTR); 
S2m = nan(nx,ny,ns,NTR); 
R2sm = nan(nx,ny,ns,NTR); 
R2m = nan(nx,ny,ns,NTR); 
NGE = pars.GESFIDE_NGE; 
NpSE = pars.GESFIDE_NpSE; 
SE_TE_ms = pars.GESFIDE_EchoTimeSE;                   
xdata = pars.EffectiveTE(2:end); 
LB = [0 0 0 0]; 
UB = [Inf Inf Inf Inf]; 
options = optimset('TolFun',1e-9,'Tolx',1e-
9,'MaxIter',2000,'Display','off'); 
%% Fitting  
%4p for baseline 
% R2 and R2* output in 1/s 
    parfor zz = 1:NTR 
        disp(zz) 
        for z = 1:ns 
           
            for y = 1:ny 
                for x = 1:nx 
                    if isnan(signal(x,y,1,z,zz)) 
                
                    else  
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                      map = squeeze(signal(x,y,:,z,zz)); 
                      x0 = [max(map) max(map) 20 40]; %initial guesses 
[S1, S2, R2*, R2]                   
                      ydata = squeeze(signal(x,y,:,z,zz)); 
                      [par4, resnorm] =  
lsqcurvefit('gesfide4p',x0,xdata,ydata',LB,UB,options,SE_TE_ms,NGE,NpSE
); 
                      S1m(x,y,z,zz) = par4(1); 
                      S2m(x,y,z,zz) = par4(2); 
                      R2sm(x,y,z,zz)= par4(3); 
                      R2m(x,y,z,zz) = par4(4); 
                      %resnormew(x,y,z,zz) = resnorm; 
                    end 
                end 
            end 
        end 
    end    
dirname = pwd; 
%Creating Structure to save T2 T2* R2 R2* S1 S2 
T2data.S1 = S1m; 
T2data.S2 = S2m; 
T2data.R2 = R2m; 
T2data.R2s = R2sm; 
%T2data.resnom = resnormew; 
%Saving Strucuture 
%save([dirname  '/T2datacorrbothlegs.mat'], 'T2data') 
%fprintf('Mapping Complete and Files Saved') 
end 
 
function [Conc] = Conc(T1,S1,T2pars) 
%%%%%%%%%%%%%%%%%%%%%%Concetration and DR1 Calculator%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%%AF Q2 2018%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%Takes in T1map and S1 from GESFIDE Output to Calculate DR1 and 
%%%%%%%Concentration. This Currently is applied for Gadvist Relaxivity 
%%%%%%%change accordingly 
[S1nx, S1ny, S1nz, S1r] = size(S1); 
r1 = 3.2;%relaxivity mmol/s 
TR = (T2pars.PVM_RepetitionTime); %ms 
alpha = str2double(T2pars.ExcPulse(11:12));%degrees 
NT1 = zeros(S1nx,S1ny,S1nz); 
NT1 = T1; 
%Refocusepulse = str2num(pars.RefPulse(27:29)); 
%TE = T2pars.PVM_EchoTime;%ms 
%Resizing T1map to Fit T2map 
  
%NT1(:,:,k) = imresize3(T1, [S1nx S1ny S1nz],'Method','linear');%ms 
  
S_ = squeeze(mean(S1(:,:,:,1:4),4));%Acquiring Signal Baseline Average 
of 10 Dynamics   
psi = S_.*(1-(exp(-TR./NT1).*cosd(alpha)));%Numerator of S0 equation 
usp = (1-exp(-TR./NT1).*sind(alpha));%Denominator of S0equation 
S0 = (psi./usp); 
parfor j = 1:S1r 
    disp(j) 
            %R1calc 
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             R1(:,:,:,j) = -(1/TR).*log((((S0.*sind(alpha) - 
S1(:,:,:,j)))./(S0.*sind(alpha)-S1(:,:,:,j).*cosd(alpha))));          
  
                   
end 
R10 = squeeze(mean(R1(:,:,:,1:4),4));%R1 pre 
clear j 
parfor j = 1:S1r 
DR1(:,:,:,j) = squeeze(R1(:,:,:,j))-R10;% 
end 
Conc = DR1.*1000/r1; 
%save('conc.mat','R1','DR1','Conc','r1') 
  
end 
%% 
 
%%%%%%%%%%%%%% TRATE Map%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%% AF Q1 2017%%%%%%%%%%%%%%%%%%%%%%%%%%% 
clear 
clc 
load('4/T1map.mat'); 
load('5/T2data.mat'); 
for k = 1:4 
NT1(:,:,k) = imresize(T1_map(:,:,k), [98 98]); 
end 
R2s = 1./T2data.T2s;%ms 
BRUKER_FILE1=['5/pdata/1/2dseq'];  
pars = readnmrpar([BRUKER_FILE1(1:end-13) 'method']); 
%% Calculate S0 of GE for R1 Solving 
%Landis Eq (4) Solving for S0 
S1 = T2data.S1; 
[nx, ny, nz, r]  =size(S1); 
%Constants 
TR = (pars.PVM_RepetitionTime); %ms 
alpha = 90; %degrees 
TE = (pars.PVM_EchoTime); %ms 
disp('R1calc') 
%S0 Clac 
%Baseline Signal 
 S_ = squeeze(mean(S1(:,:,:,1:10),4));    
 %Getting T1 
 T1 = NT1(:,:,:);%ms 
 %Calculating Numerator 
 psi = S_.*(1-(exp(-TR./T1).*cosd(alpha))); 
 %Calculating Denominator 
 usp = (1-exp(-TR./T1))*sind(alpha); 
 %S0 
 S0 = (psi./usp); 
 %R1 Calculation 
parfor j = 1:r 
    disp(j) 
            %R1calc 
            %Numerator 
            psi2 = (S0.*sind(alpha)-squeeze(S1(:,:,:,j)).*cosd(alpha)); 
            %Denominator 
            usp2 = (S0.*sind(alpha)-squeeze(S1(:,:,:,j))); 
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            %R1 
            R1(:,:,:,j) = 
(1/TR).*log((psi2./usp2).*exp(TE.*squeeze(R2s(:,:,:,j))));%1/ms         
%%% Compare with T2s and w/o 
end 
clear j g h k 
%R10 
    R10 = squeeze(mean(R1(:,:,:,1:10),4)); 
disp('DR1 Calc') 
parfor j = 1:r 
disp(j) 
%Calcualte Delta R1 
DR1(:,:,:,j) = squeeze(R1(:,:,:,j))-R10; 
end 
%% 
r1 = 3.2; %Same paper as before but the concentration 4mol at 7T Units 
~ 1/mmol-s 
%Eq 12.1  Yankeelov Pickens Price Quantitative MRI in Cancer Using 
Signal from S1 (90 flip Echo) of Gesfide Output 
Conc= (DR1.*1000)./r1; % (1/ms)/(1/mMol-s) -->*1000 ---> (1/s)/(1/mmol-
s) --> mmol   
disp('DR2scalc') 
%R20 Calculation 10 base line points 
R2s0 = squeeze(nanmean(R2s(:,:,:,1:8),4)); 
DR2s = R2s-R2s0; 
%TRATE 
TrateDR2s = squeeze(mean(DR2s(:,:,:,end-5:end),4)).*1000; 
TrateConcmap = abs(squeeze(mean(Conc(:,:,:,end-5:end),4))); 
TrateConc = squeeze(mean(Conc(:,:,:,end-5:end),4)); 
Trate= abs(TrateDR2s./TrateConc); 
%save('Tratemap.mat','Trate') 
%% Plotting Sanity Check 
figure 
imagesc(abs(Trate(:,:,2)),[0 300]) 
figure 
histogram(abs(Trate),'BinLimits',[5 250]) 
 
 
function [] = TRATE(Conc,R2s) 
%%%%%%%%%%%%%%%%%%%%%%%TRATE Calculator%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%%%%%%%%%%%% AF Q2 2018%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
%%%%%%%%%%Takes in Concentration time curve and DR2s Time Curve to 
%%%%%%%%%%calculate a map of TRATE values 
[nx, ny, nz, dyn] = size(R2s); 
R2ss = nan(nx,ny,nz,dyn); 
%Temporal Smoothing MWA size 3 
for k = 1:nz 
    for h = 1:ny 
        for g = 1:nx 
            R2ss(g,h,k,:) = smooth(R2s(g,h,k,:)); 
        end 
    end 
end 
%Concentration Filter Removing Outliers 
Conc = real(Conc); 
Cmax = squeeze(max(Conc,[],4)); 
Cmaxm = nanmean(reshape(Cmax,[98*98*6 1])); 
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Cmaxstd = nanstd(reshape(Cmax,[98*98*6 1])); 
Cmax(Cmax>(Cmaxm+Cmaxstd)) = nan; 
Cmax(Cmax<(Cmaxm-Cmaxstd)) = nan; 
Cmaxm2 = nanmean(reshape(Cmax,[98*98*6 1])); 
Cmaxstd2 = nanstd(reshape(Cmax,[98*98*6 1])); 
B = nan(98,98,6); 
B(Cmax>0) = 1; 
R2ss0 = squeeze(nanmean(R2ss(:,:,:,1:7),4)); 
for k = 1:dyn 
    DR2ss(:,:,:,k) = R2ss(:,:,:,k)-R2ss0; 
end 
A = nanmean(DR2ss(:,:,:,end-7:end),4)- nanmean(DR2ss(:,:,:,1:7),4); 
%Removing Negative Curves 
A(A<0) = nan; 
A(A>0) = 1; 
%Combining Filters 
A = A.*B; 
for k = 1:dyn 
    DR2ss(:,:,:,k) = DR2ss(:,:,:,k).*A; 
end 
for k = 1:dyn 
    Conc(:,:,:,k) = Conc(:,:,:,k).*A; 
end 
%TRATE Calculation 
TrateDR2ss = squeeze(nanmean(DR2ss(:,:,:,end-3:end),4)); 
TrateConc = squeeze(nanmean(Conc(:,:,:,end-3:end),4)); 
Trate= TrateDR2ss./TrateConc; 
save('TRATEresultpatch.mat','Trate','TrateConc','TrateDR2ss') 
end 
 
 
